^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Endometrial Cancer

    Related cancers:
    1d
    Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cervical Cancer (clinicaltrials.gov)
    P=N/A, N=600, Not yet recruiting, Asan Medical Center
    New trial • Minimal residual disease
    1d
    DOSTCONICG: The Effect of Dose and Storage Conditions of Indocyanine Green on Efficacy and Cost in Sentinel Lymph Node Mapping in Gynecological Cancer (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, Cukurova University
    New trial
    1d
    SYLVER: A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors (clinicaltrials.gov)
    P1/2, N=14, Active, not recruiting, GlaxoSmithKline | Recruiting --> Active, not recruiting | N=73 --> 14 | Trial completion date: Jun 2028 --> Jun 2026 | Trial primary completion date: Feb 2027 --> Jun 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Mismatch repair • MSI-H • dMMR
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    1d
    Mining in Endometrial Cancer Based on the TCGA Database and Constructing Prognostic Models. (PubMed, J Vis Exp)
    Nicotinamide metabolism was found to be significantly linked with EC progression. This study offers new perceptions into the role of nicotinamide metabolism in EC and suggests possible avenues for treatment advancements.
    Journal
    |
    TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • AURKA (Aurora kinase A) • CCNA2 (Cyclin A2) • CDK2 (Cyclin-dependent kinase 2) • FOXM1 (Forkhead Box M1) • CDK1 (Cyclin-dependent kinase 1) • CDK3 (Cyclin Dependent Kinase 3)
    1d
    Recent therapeutic advances in gynecologic oncology: evolving roles of immunotherapy, antibody-drug conjugates, and clinical trial innovations. (PubMed, Front Oncol)
    The analysis focuses on treatments that have demonstrated clinical benefit in advanced or recurrent disease, including pembrolizumab, dostarlimab, tisotumab vedotin, and mirvetuximab soravtansine. Their growing integration into clinical practice has reshaped therapeutic approaches, while ongoing research continues to refine optimal combinations, address resistance, and enhance biomarker-guided selection. Future developments are expected to unite immunologic, genomic, and computational strategies to achieve personalized and durable outcomes for patients with gynecologic malignancies.
    Review • Journal • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • FOLR1 ( Folate receptor alpha )
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Jemperli (dostarlimab-gxly) • Elahere (mirvetuximab soravtansine-gynx) • Tivdak (tisotumab vedotin-tftv)
    3d
    Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer (clinicaltrials.gov)
    P3, N=255, Recruiting, National Cancer Institute (NCI) | Initiation date: Oct 2026 --> Jan 2026
    Trial initiation date • pMMR
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • carboplatin • paclitaxel • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    3d
    TROPICS-03: Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors (clinicaltrials.gov)
    P2, N=223, Active, not recruiting, Gilead Sciences | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    Trodelvy (sacituzumab govitecan-hziy)
    3d
    FIH Study to Evaluate Safety, Tolerability, PK, PD & Preliminary Efficacy of AT03-65 With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=83, Recruiting, Axcynsis Therapeutics Pte Ltd | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • CLDN6 (Claudin 6)
    |
    EGFR mutation
    3d
    Evaluation of the new European risk classification for endometrial carcinoma: a cohort study. (PubMed, Int J Gynecol Cancer)
    The ESGO-ESTRO-ESP 2025 classification re-assigns approximately one-tenth of patients, with a meaningful impact on adjuvant therapy. The rarity of estrogen receptor negativity limits its role in no-specific-molecular-profile stratification. Variation in lymph node involvement across molecular tumor categories highlights opportunities for individualized surgical staging.
    Journal
    |
    ER (Estrogen receptor)
    |
    ER positive • MSI-H/dMMR • ER negative
    3d
    BRCA1 and BRCA2 carriers: Perceptions of endometrial cancer risk. (PubMed, Gynecol Oncol)
    Many carriers have limited knowledge of EC risk and do not receive consistent counseling about hysterectomy.
    Journal
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    4d
    A Randomized, Double-Blind, Placebo-Controlled Study of Vortioxetine Combination with Adjuvant Chemotherapy (With or Without Radiotherapy) for Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery with Curative Intent (ChiCTR2500109068)
    P4, N=280, Not yet recruiting, The international peace maternity and child health hospital; The international peace maternity and child health hospital | Initiation date: Oct 2025 --> Feb 2026
    Trial initiation date
    4d
    Efficacy and Safety of Senaparib Maintenance Therapy in Patients with p53-Abnormal Endometrial Carcinoma After Adjuvant Chemotherapy (ChiCTR2600116927)
    P=N/A, N=42, Not yet recruiting, Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center
    New trial
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    carboplatin • paclitaxel • Paishuning (senaparib)